Home
SCIENCE & SPACE · Discover Today in History

Streptomycin: Albert Schatz’s Breakthrough on 19 October 1943

On 19 October 1943, Albert Schatz recorded the antibiotic activity of a Streptomyces griseus culture in a Rutgers basement laboratory. The discovery opened the first effective drug attack on tuberculosis—and a long dispute over scientific credit.

Albert Schatz working in the Rutgers laboratory associated with the discovery of streptomycin
Albert Schatz at work in the Rutgers laboratory connected with the discovery of streptomycin.
SCIENCE & SPACE

Part of the Today in History: October 19 edition.

On 19 October 1943, a sealed culture tube in a Rutgers University laboratory marked the beginning of a medical transformation. Albert Schatz, a 23-year-old graduate student working in Selman Waksman’s research program, had isolated an antibiotic produced by Streptomyces griseus. The compound would be named streptomycin. It became the first antibiotic shown to be effective against tuberculosis, but the story of its discovery also became a case study in how scientific credit can be distributed—and withheld.

Albert Schatz working in the Rutgers laboratory associated with the discovery of streptomycin
Albert Schatz in the Rutgers laboratory. Institutional archival image from the Waksman Microbiology Museum.

Searching the soil for medicines

Penicillin had shown that microorganisms could yield powerful antibacterial substances, but it was not effective against every pathogen. Tuberculosis, caused by Mycobacterium tuberculosis, remained one of the world’s deadliest infectious diseases. Waksman’s laboratory pursued a systematic program of screening actinomycetes—soil-dwelling microorganisms—for substances that inhibited other microbes.

The method demanded patience. Researchers cultured organisms, tested them against target bacteria, and eliminated compounds that were too toxic or too weak. Earlier candidates such as actinomycin and streptothricin showed promise but could not safely solve the tuberculosis problem. Schatz joined the laboratory in 1943 and worked intensively with strains of Streptomyces griseus.

The tube dated 19 October

A Smithsonian-held specimen gives the date unusual physical precision. The museum describes a culture sample on agar dated 19 October 1943 and recognizes Schatz as a co-discoverer. That object anchors the anniversary more securely than a later celebratory retelling. Schatz isolated two active strains; Waksman’s broader program, laboratory resources and research direction provided the framework in which the work occurred.

The discovery did not mean that a safe treatment was ready that afternoon. Isolation was followed by purification, animal testing, clinical trials, manufacturing and careful evaluation of toxicity. Researchers at the Mayo Clinic played an important role in early clinical work. In 1944, streptomycin was given to patients with tuberculosis, and evidence accumulated that it could suppress the disease.

Two-dimensional chemical structure of streptomycin
The chemical structure of streptomycin. Educational diagram via Wikimedia Commons.

The first effective weapon against tuberculosis

For generations, tuberculosis treatment had centered on rest, nutrition, fresh air and surgery, often in sanatoria. Streptomycin changed the possibilities. It was not a perfect cure: the bacterium could develop resistance when the drug was used alone, and treatment could damage hearing or balance. Combination therapy with other drugs became essential.

Even with those limits, the breakthrough was immense. A bacterial disease that had filled hospitals and sanatoria could now be attacked chemically. Streptomycin also treated other infections and helped establish the aminoglycoside class of antibiotics. Its medical history therefore includes both life-saving efficacy and the enduring challenge of antimicrobial resistance.

Who received the credit?

Waksman’s name became internationally associated with the discovery, and he received the 1952 Nobel Prize in Physiology or Medicine “for his discovery of streptomycin.” Schatz argued that his central experimental role had been minimized. He sued Waksman and Rutgers in 1950; the settlement recognized him as a co-discoverer and awarded a share of royalties.

The dispute should not be reduced to a simple choice between lone genius and theft. Modern research is collaborative, but hierarchy determines who controls publications, patents and public narratives. Rutgers and the Smithsonian now explicitly recognize Schatz’s role. The record also preserves Waksman’s intellectual program and the contributions of other laboratory and clinical researchers.

Why the discovery still matters

Streptomycin made tuberculosis treatable but did not eliminate it. Drug-resistant strains and unequal access remain global problems. The lesson of 1943 is therefore twofold: methodical basic research can create tools that transform medicine, and every tool must be protected through responsible use.

The history of credit matters too. The tube dated 19 October is more than a scientific artifact. It is evidence that allows institutions to reconstruct who did the work, when it happened and how recognition changed afterward.

Explore more stories in Science & Space, including Chuck Yeager breaking the sound barrier, the launch of Cassini–Huygens, and Apollo 7.

From laboratory finding to clinical evidence

Once the active substance had been identified, researchers needed to know whether it could reach infected tissue at useful concentrations without causing intolerable harm. That work required chemists, microbiologists, physicians and manufacturers. The Mayo Clinic’s early studies helped establish activity against tuberculosis. Later randomized trials by Britain’s Medical Research Council became landmarks in the evaluation of treatment.

Streptomycin monotherapy quickly demonstrated another biological fact: bacterial populations evolve. Some organisms survived and multiplied, producing resistant disease. Combining drugs with different mechanisms reduced that risk. Modern tuberculosis therapy grew from this lesson, using multi-drug regimens over sustained periods rather than relying on a single celebrated molecule.

The object as historical evidence

The Smithsonian culture tube is especially powerful because it joins material evidence to institutional records. A label, a date and the organism preserved in glass connect a broad medical narrative to a specific laboratory practice. Museums preserve such objects not because a tube alone explains discovery, but because it can test and refine later claims about priority.

The same applies to notebooks, patent files, correspondence and publication drafts in the Rutgers archives. Together they show how a discovery moves through stages: experiment, naming, announcement, validation, patenting and commemoration. Credit can shift at each stage. Schatz’s later recognition did not erase Waksman’s direction of the screening program; it corrected a public story that had made the experimental contribution too invisible.

Sources and method

Exact-date evidence was checked against the Smithsonian object record; institutional histories from Rutgers and the American Chemical Society were used for the laboratory program, medical significance and credit dispute. References: Smithsonian, Streptomyces griseus specimen; Rutgers, Streptomycin and the Waksman legacy; ACS National Historic Chemical Landmark.

Editorial standard: researched and fact-checked by Discover Today in History; last reviewed for the 19 October 2026 edition.

Continue Reading

Leave a Comment

Your email address will not be published. Required fields are marked *

*